

Paxman publishes newsletter on a significant step forward for scalp cooling access in the United States

Today, Paxman publishes the November issue of its newsletter aimed at shareholders, investors and other interested parties.

This month's issue highlights that The US Centers for Medicare & Medicaid Services (CMS) has reassigned payment for scalp cooling for Medicare claims filed using CPT code 0662T to New Technology APC 1520, with a National Average Payment of 1,850.50 USD, effective January 1, 2022. This is a significant step forward for cancer chemotherapy patients across the US that will ensure strong expansion of patient access to scalp cooling.

The newsletter also includes information on the opening of a clinical trial with National University Hospital, Singapore, in collaboration with The N.1 Institute for Health, National University of Singapore, to investigate the safety and tolerability of limb cryocompression in preventing of chemotherapy-induced peripheral neuropathy (CIPN) via the newly developed Paxman Cryocompression System (PCCS) in healthy subjects and cancer patients, several orders and installs in the UK and internationally, and the appointment of a new distribution partner for Uruguay.

To read the newsletter and subscribe for upcoming issues, follow this link:

<https://bit.ly/paxnov21en>

Paxman's investor newsletter is published monthly as a part of the company's effort to strengthen its market communication together with the IR communication agency [Honeybadger](#). Every published issue of the newsletter is available on Paxman's website for investors, www.paxman.se. The company encourages feedback and requests on topics for upcoming issues of the newsletter.

Contacts

Richard Paxman, CEO
Tel: +44 7968 020641
Email: richard@paxmanscalpcooling.com
www.paxman.se

About Us

The Paxman Scalp Cooling System has been developed by the Paxman family to reduce hair loss in breast cancer patients undergoing chemotherapy. The concept behind the system came when the mother of four, Sue Paxman, experienced first-hand the trauma of chemotherapy-induced hair loss. With close to 3,500 systems delivered in to hospitals, clinics and treatment centres around the world, PAXMAN is the leading supplier of Scalp Cooling technology. PAXMAN's scalp-cooling cap is made from lightweight, biocompatible silicone that is soft and flexible, providing a snug yet comfortable fit during treatment. PAXMAN AB (publ) has its headquarters in Karlshamn (Sweden), with subsidiaries in Huddersfield (UK) and Houston, Texas (US).

The PAXMAN share is listed on Nasdaq First North Growth Market. FNCA Sweden AB is the company's Certified Adviser and can be contacted via info@fnca.se and +46 (0)8 528 003 99.

Attachments

[Paxman publishes newsletter on a significant step forward for scalp cooling access in the United States](#)